All In Biotech

Drug Trial Radar · NCT07124884

5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab

COLOSOTO: Single-arm Phase II Study Evaluating 5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab

Last checked: Nov 20, 2026Latest source record: Aug 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Aug 31, 2025

Primary completion

Jun 30, 2030

Study completion Dec 30, 2030

Sponsor

Lead sponsor
Federation Francophone de Cancerologie DigestiveAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Northwest Oncology Cooperative Group(GONO); Arbeitsgemeinschaft fur Internistische Onkologie; Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
First posted
Aug 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

5-fluorouracil (5-FU) is a standard of care in frail/elderly patients with an unresectable colorectal adenocarcinoma (CRC) in first-line setting. Panitumumab plus Sotorasib are promising in advanced line in KRAS G12C mutated CRC. In this study, We assess the safety and efficacy of 5FU combination with Panitumumab and Sotorasib as first-line treatment in frail/elderly patients with unresectable KRAS G12C mutated CRC

Conditions

  • Colorectal Carcinoma
  • KRAS G12C Mutation
  • Unresectable Colorectal Cancer

Interventions

  • Administration of experimental treatment association (sotorasib, panitumumab 5FU)Drug

    Panitumumab is administered at a dose of 6 mg/kg via intravenous infusion over one hour during the first cycle, and over 30 minutes from the second cycle onward. The LV5FU2 regimen includes folinic acid (400 mg/m², or 200 mg/m² if levo-leucovorin is used) as a two-hour IV infusion, followed by a 5-FU bolus (400 mg/m² over 10 minutes), and a continuous 5-FU infusion (2400 mg/m² over 46 hours). Sotorasib is given orally at a dose of 960 mg once daily on a continuous basis.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of patient alive or without progression 8 months after inclusion.Time frame: at 8 months after the inclusion.

Locations

80 sites in 4 countries. Site status is shown where the registry gives one.

  • ICO site Paul Papin

    Angers, France

  • Centre Hospitalier Annecy Genevois

    Annecy, France

  • Hôpital Privé

    Antony, France

  • Centre Hospitalier

    Aurillac, France

  • Centre Hospitalier

    Bayeux, France

  • Ch Cote Basque

    Bayonne, France

  • Ch Simone Veille

    Beauvais, France

  • Chu Jean Minjoz

    Besançon, France

  • Centre Hospitalier Béthune Beuvry

    Béthune, France

  • Polyclinique Courlancy

    Bezannes, France

  • Bordeaux Nord Aquitaine

    Bordeaux, France

  • TIVOLI

    Bordeaux, France

  • Chu Morvan

    Brest, France

  • CHU Côte de Nacre

    Caen, France

  • Centre Hospitalier

    Cholet, France

  • Hôpitaux civils

    Colmar, France

  • Polyclinique Saint-Côme

    Compiègne, France

  • Chu Francois Mitterand

    Dijon, France

  • Gf Leclerc

    Dijon, France

  • Institut de cancérologie de Bourgogne GRReCC

    Dijon, France

  • Groupe Hospitalier Mutualiste

    Grenoble, France

  • Chd Vendee

    La Roche-sur-Yon, France

  • Hôpital Franco Britannique

    Levallois-Perret, France

  • Hôpital Privé Le Bois

    Lille, France

  • CHU Dupuytren

    Limoges, France

  • Groupe Hospitalier Bretagne Sud

    Lorient, France

  • Hôpital Jean Mermoz

    Lyon, France

  • Chu La Timone

    Marseille, France

  • Hôpital Européen

    Marseille, France

  • CHRU

    Nancy, France

  • Gh Nord Essone

    Orsay, France

  • Chu Cochin

    Paris, France

  • HEGP

    Paris, France

  • Montsouris

    Paris, France

  • Saint-Louis

    Paris, France

  • Centre Hospitalier

    Pau, France

  • CHU Haut Leveque

    Pessac, France

  • Centre Cario

    Plérin, France

  • Chu La Miletrie

    Poitiers, France

  • CH Quimper Concarneau

    Quimper, France

Showing 40 of 80 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.